Business US
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? – MarketWatch
- How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? MarketWatch
- Novo takes another shot at Lilly The Economist
- Lilly climbs, Novo falls as obesity drug battle intensifies BioPharma Dive
- Novo vs. Lilly: Q2’s cardiometabolic grudge match Endpoints News
- Obesity battle heats up again as Novo claws way back into race with Lilly Reuters
